Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAINRITSys: rituximab maintenance versus placebo in systemic sclerosis-associated interstitial lung disease
2025-521331-36-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab and sodium chloride in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Absolute change in forced vital capacity. Planned start May 2026; status: authorised.
02
Drugs
rituximabsodium chloride
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on 2025-521331-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521331-36-00.